Trials have shown that granulocyte colony-stimulating factor (G-CSF) has the potential to reduce the duration of neutropenia, thereby preserving the therapeutic benefit of venetoclax by avoiding premature discontinuation. Here, CSF3 is linked to Decreased total neutrophil count.